What is Royalty Pharma Plc's earnings per share (EPS)?

Royalty Pharma Plc (RPRX) reported diluted earnings per share of $1.78 for fiscal year 2025. This represents a -6.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Royalty Pharma Plc Financials

RPRX

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Royalty Pharma Plc (RPRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RPRX FY2025 2026-05-06

Steady cash harvesting funds balance-sheet reinvestment, while reported earnings swing far more than the underlying business cash flow.

In every recent valid year, operating cash flow stayed above $2.1B while net income fell as low as $42.8M. Because that cash-profit gap persisted through both weak and strong earnings years, the core economics appear steadier than headline profit suggests, and management seems to allocate against cash receipts rather than waiting for accounting profit to smooth out.

FY2025 paired higher leverage with comfortable short-term coverage: debt to equity rose to 88.2% and long-term debt reached $8.6B. Yet the current ratio was 2.4x, which points to obligations that are mainly long-dated rather than a business being squeezed by immediate payables or working-capital needs.

The company looks extremely high-margin on the income statement, with FY2025 operating margin at 65.6%, but it is only moderately productive on its asset base, with return on assets at 3.9%. That tells you each revenue dollar is structurally rich, while the balance sheet required to sustain and replenish those cash streams is much heavier than the margin alone implies.

Financial Health Signals

Financial Health Score 44/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Royalty Pharma Plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Royalty Pharma Plc has an operating margin of 65.6%, meaning the company retains $66 of operating profit per $100 of revenue. This strong profitability earns a score of 88/100, reflecting efficient cost management and pricing power. This is up from 57.1% the prior year.

Growth

Royalty Pharma Plc's revenue grew 5.1% year-over-year to $2.4B, a solid pace of expansion. This earns a growth score of 34/100.

Leverage

Royalty Pharma Plc has elevated debt relative to equity (D/E of 0.88), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 11/100, reflecting increased financial risk.

Liquidity

With a current ratio of 2.40, Royalty Pharma Plc holds $2.40 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 67/100.

Returns

Royalty Pharma Plc's ROE of 7.9% shows moderate profitability relative to equity, earning a score of 62/100. This is down from 8.3% the prior year.

Altman Z-Score Grey Zone

2.19

Royalty Pharma Plc scores 2.19, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($26.1B) relative to total liabilities ($9.9B). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/7

Royalty Pharma Plc passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

3.23x

For every $1 of reported earnings, Royalty Pharma Plc generates $3.23 in operating cash flow ($2.5B OCF vs $770.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.1x

Royalty Pharma Plc earns $5.1 in operating income for every $1 of interest expense ($1.6B vs $307.7M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.4B

YoY+5.1%

5Y CAGR+2.3%

Royalty Pharma Plc generated $2.4B in revenue in fiscal year 2025. This represents an increase of 5.1% from the prior year.

EBITDA

$1.6B

YoY+21.0%

Royalty Pharma Plc's EBITDA was $1.6B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 21.0% from the prior year.

Net Income

$770.9M

YoY-10.2%

5Y CAGR-4.6%

Royalty Pharma Plc reported $770.9M in net income in fiscal year 2025. This represents a decrease of 10.2% from the prior year.

EPS (Diluted)

$1.78

YoY-6.8%

5Y CAGR+6.2%

Royalty Pharma Plc earned $1.78 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 6.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$618.7M

YoY-33.4%

5Y CAGR-9.3%

Royalty Pharma Plc held $618.7M in cash against $8.6B in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

65.6%

YoY+8.5pp

5Y CAGR-9.6pp

Royalty Pharma Plc's operating margin was 65.6% in fiscal year 2025, reflecting core business profitability. This is up 8.5 percentage points from the prior year.

Net Margin

32.4%

YoY-5.5pp

5Y CAGR-13.5pp

Royalty Pharma Plc's net profit margin was 32.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 5.5 percentage points from the prior year.

Return on Equity

7.9%

YoY-0.4pp

5Y CAGR-1.9pp

Royalty Pharma Plc's ROE was 7.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$452.0M

YoY+22500.0%

5Y CAGR+76.6%

Royalty Pharma Plc invested $452.0M in research and development in fiscal year 2025. This represents an increase of 22500.0% from the prior year.

Share Buybacks

$1.2B

YoY+434.5%

Royalty Pharma Plc spent $1.2B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 434.5% from the prior year.

Capital Expenditures

N/A

RPRX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.4B+5.1%	$2.3B-3.9%	$2.4B+5.2%	$2.2B-2.3%	$2.3B+7.9%	$2.1B
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$452.0M+22500.0%	$2.0M-96.2%	$52.0M-70.6%	$177.1M-11.5%	$200.1M+661.1%	$26.3M
SG&A Expenses	$573.5M+142.3%	$236.7M-5.2%	$249.7M+9.9%	$227.3M+24.3%	$182.8M+0.6%	$181.7M
Operating Income	$1.6B+20.7%	$1.3B-13.4%	$1.5B+385.9%	$307.1M-78.5%	$1.4B-10.3%	$1.6B
Interest Expense	$307.7M+36.4%	$225.5M+20.5%	$187.2M-0.4%	$188.0M+13.1%	$166.1M+5.8%	$157.1M
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	$770.9M-10.2%	$859.0M-24.3%	$1.1B+2549.5%	$42.8M-93.1%	$619.7M-36.4%	$975.0M
EPS (Diluted)	$1.78-6.8%	$1.91-24.5%	$2.53+2430.0%	$0.10-93.3%	$1.49+12.9%	$1.32

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$630.6M+1.4%	$622.0M+2.1%	$609.3M+5.3%	$578.7M+1.8%	$568.2M-4.3%	$593.6M+5.1%	$564.7M+5.1%	$537.3M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$39.8M-21.2%	$50.5M0.0%	$50.5M-83.2%	$300.5M+495.0%	$50.5M+10000.0%	$500K0.0%	$500K0.0%	$500K
SG&A Expenses	$159.5M-2.9%	$164.3M+38.4%	$118.7M-34.0%	$179.8M+62.4%	$110.7M+63.8%	$67.6M+19.2%	$56.7M+3.7%	$54.7M
Operating Income	$563.0M+45.0%	$388.4M-9.1%	$427.2M+103.6%	$209.8M-60.7%	$534.2M+47.8%	$361.5M-50.8%	$735.1M+172.6%	$269.6M
Interest Expense	$93.7M-0.5%	$94.2M+18.4%	$79.6M+15.9%	$68.7M+5.2%	$65.3M-0.8%	$65.8M-1.1%	$66.5M+35.7%	$49.0M
Income Tax	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	$294.7M+38.2%	$213.2M-26.0%	$288.2M+855.1%	$30.2M-87.4%	$239.3M+15.0%	$208.2M-61.7%	$544.0M+433.3%	$102.0M
EPS (Diluted)	$0.67	N/A	$0.67+857.1%	$0.07-87.3%	$0.55	N/A	$1.21+426.1%	$0.23

RPRX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$19.6B+7.7%	$18.2B+11.2%	$16.4B-2.6%	$16.8B-4.0%	$17.5B+9.3%	$16.0B
Current Assets	$1.5B-15.2%	$1.8B+41.4%	$1.3B-50.1%	$2.6B-11.2%	$2.9B+6.7%	$2.7B
Cash & Equivalents	$618.7M-33.4%	$929.0M+94.8%	$477.0M-72.1%	$1.7B+11.0%	$1.5B+52.8%	$1.0B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$924.6M	$0	N/A	N/A	N/A	N/A
Total Liabilities	$9.9B+25.7%	$7.9B+25.1%	$6.3B-13.6%	$7.3B+0.3%	$7.3B+18.7%	$6.1B
Current Liabilities	$636.2M-49.2%	$1.3B+676.8%	$161.4M-86.2%	$1.2B+581.3%	$171.3M-44.4%	$307.9M
Long-Term Debt	$8.6B+29.6%	$6.6B+7.8%	$6.1B+0.3%	$6.1B-13.8%	$7.1B+22.0%	$5.8B
Total Equity	$9.7B-6.1%	$10.3B+2.6%	$10.1B+5.9%	$9.5B-7.1%	$10.2B+3.6%	$9.9B
Retained Earnings	$2.4B-17.2%	$2.8B+13.0%	$2.5B+28.1%	$2.0B-12.9%	$2.3B+17.4%	$1.9B

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$19.8B+1.0%	$19.6B+1.4%	$19.3B+5.6%	$18.3B+4.1%	$17.6B-3.4%	$18.2B+1.0%	$18.0B+2.2%	$17.7B
Current Assets	$1.4B-6.7%	$1.5B-17.4%	$1.8B+21.7%	$1.5B-17.5%	$1.8B+2.3%	$1.8B+0.4%	$1.8B-30.4%	$2.6B
Cash & Equivalents	$586.4M-5.2%	$618.7M-34.1%	$938.9M+48.6%	$631.9M-41.9%	$1.1B+17.1%	$929.0M-2.2%	$950.1M-46.2%	$1.8B
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$924.6M0.0%	$924.6M0.0%	$924.6M0.0%	$924.6M	N/A	$0	N/A	N/A
Total Liabilities	$9.9B-0.3%	$9.9B+1.8%	$9.7B+10.3%	$8.8B+12.8%	$7.8B-0.8%	$7.9B+1.2%	$7.8B-1.5%	$7.9B
Current Liabilities	$535.7M-15.8%	$636.2M+19.9%	$530.8M-56.0%	$1.2B+2.0%	$1.2B-5.6%	$1.3B+7.4%	$1.2B+323.6%	$275.7M
Long-Term Debt	$8.6B+0.1%	$8.6B+0.1%	$8.6B+22.3%	$7.0B+5.8%	$6.6B+0.1%	$6.6B+0.1%	$6.6B-13.0%	$7.6B
Total Equity	$9.9B+2.3%	$9.7B+1.0%	$9.6B+1.2%	$9.5B-2.8%	$9.8B-5.5%	$10.3B+0.8%	$10.3B+5.2%	$9.8B
Retained Earnings	$2.5B+6.4%	$2.4B+2.3%	$2.3B+3.7%	$2.2B-10.4%	$2.5B-12.8%	$2.8B+2.9%	$2.8B+16.2%	$2.4B

RPRX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$2.5B-10.1%	$2.8B-7.3%	$3.0B+39.4%	$2.1B+6.3%	$2.0B-0.8%	$2.0B
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$1.6B+39.7%	-$2.7B-29.2%	-$2.1B-101.4%	-$1.0B+45.0%	-$1.9B+32.2%	-$2.8B
Financing Cash Flow	-$1.2B-428.4%	$361.1M+116.8%	-$2.1B-127.4%	-$944.9M-345.3%	$385.1M-74.1%	$1.5B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$1.2B+434.5%	$229.7M-24.6%	$304.8M	$0	$0	$0

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$718.2M-13.2%	$827.1M+17.7%	$702.6M+93.0%	$364.0M-38.9%	$596.1M-19.7%	$742.5M+5.5%	$703.6M+6.9%	$658.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$477.9M+43.6%	-$847.8M+11.5%	-$958.3M-207.2%	-$312.0M-161.9%	$503.9M+199.7%	-$505.6M+57.6%	-$1.2B-33.5%	-$893.2M
Financing Cash Flow	-$272.7M+9.0%	-$299.6M-153.2%	$562.7M+210.8%	-$507.8M+46.1%	-$941.3M-264.9%	-$258.0M+20.7%	-$325.5M-128.1%	$1.2B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$50.1M-37.8%	$80.5M-45.0%	$146.5M-49.8%	$291.6M-58.9%	$708.8M+1247.3%	$52.6M-45.8%	$97.0M+21.3%	$80.0M

RPRX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	65.6%+8.5pp	57.1%-6.3pp	63.4%+49.6pp	13.7%-48.8pp	62.5%-12.7pp	75.2%
Net Margin	32.4%-5.5pp	38.0%-10.2pp	48.2%+46.3pp	1.9%-25.2pp	27.1%-18.9pp	45.9%
Return on Equity	7.9%-0.4pp	8.3%-2.9pp	11.3%+10.8pp	0.4%-5.6pp	6.0%-3.8pp	9.8%
Return on Assets	3.9%-0.8pp	4.7%-2.2pp	6.9%+6.7pp	0.3%-3.3pp	3.5%-2.6pp	6.1%
Current Ratio	2.40+1.0	1.44-6.5	7.90+5.7	2.19-14.6	16.81+8.0	8.76
Debt-to-Equity	0.88+0.2	0.64+0.0	0.61-0.0	0.64-0.1	0.69+0.1	0.59
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	89.3%+26.9pp	62.4%-7.7pp	70.1%+33.8pp	36.3%-57.8pp	94.0%+33.1pp	60.9%-69.3pp	130.2%+80.0pp	50.2%
Net Margin	46.7%+12.4pp	34.3%-13.0pp	47.3%+42.1pp	5.2%-36.9pp	42.1%+7.1pp	35.1%-61.3pp	96.3%+77.3pp	19.0%
Return on Equity	3.0%+0.8pp	2.2%-0.8pp	3.0%+2.7pp	0.3%-2.1pp	2.5%+0.4pp	2.0%-3.3pp	5.3%+4.3pp	1.1%
Return on Assets	1.5%+0.4pp	1.1%-0.4pp	1.5%+1.3pp	0.2%-1.2pp	1.4%+0.2pp	1.1%-1.9pp	3.0%+2.4pp	0.6%
Current Ratio	2.66+0.3	2.40-1.1	3.48+2.2	1.26-0.3	1.56+0.1	1.44-0.1	1.54-7.8	9.35
Debt-to-Equity	0.86-0.0	0.880.0	0.89+0.2	0.74+0.1	0.68+0.0	0.640.0	0.64-0.1	0.78
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

BIONTECH BNTX

$22.6B

Genmab GMAB

$17.7B

Incyte Corp INCY

$23.5B

Summit Therapeutics Inc SMMT

$10.9B

Insmed Inc INSM

$23.2B

Frequently Asked Questions

What is Royalty Pharma Plc's annual revenue?

Royalty Pharma Plc (RPRX) reported $2.4B in total revenue for fiscal year 2025. This represents a 5.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Royalty Pharma Plc's revenue growing?

Royalty Pharma Plc (RPRX) revenue grew by 5.1% year-over-year, from $2.3B to $2.4B in fiscal year 2025.

Is Royalty Pharma Plc profitable?

Yes, Royalty Pharma Plc (RPRX) reported a net income of $770.9M in fiscal year 2025, with a net profit margin of 32.4%.

What is Royalty Pharma Plc's EBITDA?

Royalty Pharma Plc (RPRX) had EBITDA of $1.6B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Royalty Pharma Plc have?

As of fiscal year 2025, Royalty Pharma Plc (RPRX) had $618.7M in cash and equivalents against $8.6B in long-term debt.

What is Royalty Pharma Plc's operating margin?

Royalty Pharma Plc (RPRX) had an operating margin of 65.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Royalty Pharma Plc's net profit margin?

Royalty Pharma Plc (RPRX) had a net profit margin of 32.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Royalty Pharma Plc's return on equity (ROE)?

Royalty Pharma Plc (RPRX) has a return on equity of 7.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Royalty Pharma Plc's operating cash flow?

Royalty Pharma Plc (RPRX) generated $2.5B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Royalty Pharma Plc's total assets?

Royalty Pharma Plc (RPRX) had $19.6B in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Royalty Pharma Plc spend on research and development?

Royalty Pharma Plc (RPRX) invested $452.0M in research and development during fiscal year 2025.

Does Royalty Pharma Plc buy back shares?

Yes, Royalty Pharma Plc (RPRX) spent $1.2B on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

What is Royalty Pharma Plc's current ratio?

Royalty Pharma Plc (RPRX) had a current ratio of 2.40 as of fiscal year 2025, which is generally considered healthy.

What is Royalty Pharma Plc's debt-to-equity ratio?

Royalty Pharma Plc (RPRX) had a debt-to-equity ratio of 0.88 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Royalty Pharma Plc's return on assets (ROA)?

Royalty Pharma Plc (RPRX) had a return on assets of 3.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Royalty Pharma Plc's Altman Z-Score?

Royalty Pharma Plc (RPRX) has an Altman Z-Score of 2.19, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Royalty Pharma Plc's Piotroski F-Score?

Royalty Pharma Plc (RPRX) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Royalty Pharma Plc's earnings high quality?

Royalty Pharma Plc (RPRX) has an earnings quality ratio of 3.23x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Royalty Pharma Plc cover its interest payments?

Royalty Pharma Plc (RPRX) has an interest coverage ratio of 5.1x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Royalty Pharma Plc?

Royalty Pharma Plc (RPRX) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.